TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04248868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bashir™ Endovascular Catheter
Description: The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-tPA
Description: Pulse spray and infusion
Study: NCT00850915

Intervention type: OTHER
Group type: OTHER
Intervention: community IPT
Description: In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB.

Intervention type: OTHER
Group type: OTHER
Intervention: community IPT
Description: In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB.
Study: NCT00944359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily preventive Zn; placebo treatment
Description: 7 mg zinc / day and placebo supplement during diarrhea episodes

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Therapeutic Zn; daily placebo
Description: 20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Zn; placebo treatment
Description: 10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surveillance control group
Description: Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
Study: NCT03003104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMT210 Topical Gel 5%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Study: NCT03690804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evaluation of Autonomic nervous system indices
Description: The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
Study: NCT02446275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid MTRP and stretching
Description: The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trapezius MTRP and stretching
Description: The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
Study: NCT02483468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Pain
Description: Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Pain
Description: Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Electrical stimulation of the prefrontal cortex using 2mA of direct current

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham stimulation of the left dorsolateral prefrontal cortex
Study: NCT00585546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clenbuterol
Description: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
Study: NCT01689623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
Study: NCT02558972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Northera (Droxidopa)
Description: Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
Study: NCT02496390

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous
Description: Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
Study: NCT01689623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
Study: NCT02496390

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic
Description: Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
Study: NCT01784107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belotecan and Ifosfamide
Study: NCT02880930

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fultium-D3 drops (Internis)
Description: Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
Study: NCT02239562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sPIF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sPIF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sPIF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sPIF
Study: NCT01649544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPICOR
Description: Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
Study: NCT02239562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sPIF
Study: NCT01649544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Study: NCT02239562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sPIF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01225211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet.
Study: NCT00996281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Combination tablet.
Study: NCT01225211

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lumacaftor Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lumacaftor Placebo
Description: Matching placebo tablet.
Study: NCT01225211

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lumacaftor Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor Placebo
Description: Matching placebo tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor Placebo
Description: Matching placebo tablet.
Study: NCT02904512

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
Description: Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Point of Care (POC) blood glucose
Description: Testing Blood Glucose levels with Point of Care (POC) blood glucose
Study: NCT03527095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Description: CFTR corrector
Study: NCT04202692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet
Description: 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet
Description: 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo 1100 mg, identically-looking melt in mouth tablet
Description: 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1100 mg, identically-looking melt in mouth tablet
Description: 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
Study: NCT04090840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Time restricted eating for 8 hours per day, with 16 hour fast. During the daily fast, patients are encouraged to drink water, black coffee, or green tea without sugar, cream, milk, or sweeteners.
Study: NCT01866501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal Humerus Intraosseous Vascular Access
Description: Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
Study: NCT01693562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
Study: NCT02427191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmnioFix® Injectable
Description: 1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Injection of 1mL 0.9% Sodium Chloride Injection, USP
Study: NCT02336802

Intervention type: BEHAVIORAL
Intervention: Avoidance experiment
Description: Participants complete an avoidance task

Intervention type: BEHAVIORAL
Intervention: Avoidance experiment
Description: Participants complete an avoidance task

Intervention type: BEHAVIORAL
Intervention: Avoidance experiment
Description: Participants complete an avoidance task
Study: NCT01693562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Participants will receive IV infusion of MEDI4736 for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
Study: NCT00996281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil and hydrochlorothiazide
Description: Combination tablet.
Study: NCT03777709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAITH! App
Description: Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
Study: NCT04152655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idebenone
Description: 30mg tablets three times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo tablets three times a day
Study: NCT03679078

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IDDSI nutritional supplement drink
Description: ready-to-use nutritional supplement drink to be taken daily for 28 days
Study: NCT04285307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene tips
Description: Students receive a packet of information on how to improve their sleep habits and hygiene.
Study: NCT03622112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 DPI 55μg/50μg.
Description: A non-steroidal and selective modulator of the GR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 DPI 99 µg/90 µg
Description: A non-steroidal and selective modulator of the GR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 DPI 198 µg/180 µg
Description: A non-steroidal and selective modulator of the GR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 DPI 396 µg/360 µg once daily.
Description: A non-steroidal and selective modulator of the GR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594 DPI 792 µg/720 µg
Description: A non-steroidal and selective modulator of the GR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for AZD7594 once daily.
Description: Placebo for AZD7594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF 100 µg once daily (open-label)
Description: Fluticasone furoate
Study: NCT01234805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: yoga therapy
Description: Participates in yoga classes and yoga at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies